Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Sanofi and GSK are touting their latecomer protein-based Covid-19 vaccine as a potential game changer in the fight against the Omicron variant.
Interview with Russ Fadel, Augmentir
Interview with Joachim Haupt and Florian Kaiser, PharmAI
The value in applying AI in Pharma is in making new and better drugs available faster than would be possible otherwise. By augmenting sparse-data AI with expert knowledge and applying it to the latest nanoparticle engineering techniques, opportunities are created to eliminate the risk associated with new techniques and give therapeutics a second chance to reach the patients who need them.
Interview with Pedro Lopes, FastCompChem
Interview with Jens Schmidt, ReCarbonX
Interview with Steven De Laet, InOpSys
Interview with Oliver Reimann and Andreas Regnery, Belyntic
Interview with Jere Koskinen and Ali Harlin, Mega Cellulose.
B4Plastics is a Belgium-based biotechnology start-up and a polymer architecture company looking to catalyze the introduction of novel biomaterials and growing them from niche to bulk applications.
Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.
Plafco Fibertech, founded in 2017, was created as a spin-off from an EU-research project coordinated by Jukka Valkama, a professor at the Cooperative State University of Baden Wurttemberg in Karlsruhe, Germany.
LipoCoat is a biotech company specialized in ‘bio-inspired’ coatings that improve the safety, comfort, and performance of medical devices with a focus on health and nutrition.
Recent studies show that contract manufacturers for the pharmaceutical industry, so-called CDMOs (contract development and manufacturing organizations), have so far been little involved in the production of vaccines. This is changing with the outbreak of the Covid-19 pandemic.
Tsubame BHB was established in April of 2017 based on a new catalyst technology developed by Prof. em. Hideo Hosono at the Tokyo Institute of Technology (Tokyo Tech), which allows an ammonia process at lower temperature and pressure.
Affix Labs over the past 5 years has specialized in binding technologies and commercialized first products in 2019.
Hafnium Labs is tackling one of the toughest challenges in chemical R&D: Obtaining reliable physical property data — fast.
In January, Schrödinger, a provider of integrated software solutions, and the life sciences company Bayer announced a 5-year technology alliance to develop a comprehensive de novo design solution to accelerate the discovery of innovative, high-quality drugs.
Online Monitoring and Control of Bioreactors by Mid-Infrared Spectroscopy
Single-step, Ambient, Dry Grafting of Organic Compounds and Biomolecules onto any Substrate.
Hybrid assemblies, joints of dissimilar materials, are everywhere - in our smartphones, cars, TVs, dishwashers, in planes and so on. However, in modern products we increasingly rely on plastics, which are intrinsically hard to bond to other types of material — and by using industrial glue for the bonding the parts cannot be recycled easily. Solving this monumental challenge inspired the foundation of the Danish start-up company RadiSurf five years ago.
Molecule.one leverages artificial intelligence (AI) to design novel chemical syntheses. As a response to the outbreak of the Covid-19 pandemic, the Polish start-up based in Warsaw has set out on the mission to accelerate the process of creating medicines.
Iris.ai was founded at Singularity University at NASA Ames Research Park in 2015. Challenged to come up with an idea that would positively impact the lives of 1 billion people, the team was formed and problem areas were explored.
New therapies to address unmet and emerging medical needs are being discovered at an explosive rate, building on rapid advances in molecular biology and genetics.
